HHS faults FDA for inadequate oversight of REMS

02/13/2013 | Pharmalot.com · Forbes · St. Louis Post-Dispatch

The HHS inspector general's office released a report saying the FDA, despite its Risk Evaluation and Mitigation Strategies program, failed to acquire crucial data from drugmakers regarding use of the riskiest medicines. Patients are more vulnerable to serious side effects because the plans' goals are not being met, the report says.

View Full Article in:

Pharmalot.com · Forbes · St. Louis Post-Dispatch

Published in Briefs: